Skip to main content
Premium Trial:

Request an Annual Quote

Knobloch Sizes Down for Bigger Challenge

Premium

His new environment is a challenge, but Christian Knobloch, new vice president of business development at EuroProteome, is enjoying the change of scenery. Not only does he get to enjoy the up-and-coming area of Hennigsdorf near Berlin, but he also gets to move from a 1,000-person company to a faster-paced one where the head count is about 25.

EuroProteome uses mass spec and other proteomics technologies as well as bioinformatics tools to design diagnostics and therapeutics for epithelial cancers. Knobloch’s role is to seek out more business opportunities for what the company’s been doing.

He left his former job at Knoll, the pharmaceutical arm of BASF, late last year to join the venture-financed startup at the beginning of this year. Among his plans for EuroProteome: “to increase [the staff] to about 50 to 60,” he says. An IPO may also be in the offing, but there are no set plans for it. “Like with every startup, an IPO is the mid- and long-term goal.”

The startup atmosphere is agreeing with Knobloch. He explains that he likes the idea of achieving success not just by continuing to sell an old product but by creating a whole new business.

Though he has a background in oncology and immunology, it’s actually the business that’s most intriguing to Knobloch. “It’s on the edge between science and commerce — that’s an area I just find very interesting in general.” And unlike larger organizations where he’d be more narrowly focused, “the scope of responsibility I have here is truly a global one. I can work internationally,” he says.

— Meredith Salisbury

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.